Heparin

Generic Name: Heparin

Brand Names: Heparin Leo

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 9005-49-6

Unique Ingredient Identifier: T2410KM04A

Background: Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...

Indication: Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...

Associated Conditions: Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein

Associated Therapies: Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices

Clinical Trials

EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding

Phase 4

Conditions: Coronary Artery Disease

Interventions: Drug: Bivalirudin
Drug: Heparin

First Posted Date: 2010-03-11

Last Posted Date: 2018-01-31

Lead Sponsor: Laval University

Target Recruit Count: 2000

Registration Number: NCT01084993

Locations: 🇨🇦
Quebec Heart-Lung Institute, Quebec, Canada

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

Conditions: Type 1 Diabetes Mellitus

First Posted Date: 2010-01-14

Last Posted Date: 2014-06-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01049633

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Heparin Resistance: Predictors and Outcomes

Not Applicable

Completed

Conditions: Off Pump Coronary Artery Bypass Surgery

First Posted Date: 2010-01-08

Last Posted Date: 2012-02-02

Lead Sponsor: Yonsei University

Target Recruit Count: 199

Registration Number: NCT01044888

Locations: 🇰🇷
Yonsei University Severance hospital, Seoul, Seodaemungu, Korea, Republic of

Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction

Phase 4

Conditions: Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Clopidogrel
Drug: Bivalirudin
Drug: Heparin

First Posted Date: 2009-09-14

Last Posted Date: 2014-01-07

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 548

Registration Number: NCT00976092

Locations: 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Bavaria, Germany
🇩🇪
Klinikum rechts der Isar, Technische Universitaet Muenchen, Munich, Bavaria, Germany
🇩🇪
Herzzentrum der Segeberger Kliniken, Bad Segeberg, Germany

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

Phase 2

Completed

Conditions: Acute Coronary Syndrome (ACS)

Interventions: Drug: REG1
Drug: Heparin

First Posted Date: 2009-07-03

Last Posted Date: 2012-03-02

Lead Sponsor: Regado Biosciences, Inc.

Target Recruit Count: 640

Registration Number: NCT00932100

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Temple University, Philadelphia, Pennsylvania, United States

and more 39 locations